830 WINTER ST, WALTHAM, MA
News, Articles of Incorporation, Bylaws
Other Events
Shareholder votes
To Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio
Reports Recent Progress and Third Quarter 2023 Financial Results
Q3
Q2
Q1
FY 2022
FY 2021
Notice of Suspension of Duty to File Reports
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Additional Proxy Materials
Definitive Merger Proxy Statement
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
S-8 POS